First bivalent COVID-19 booster vaccine approved by UK medicines regulator
The adapted COVID-19 vaccine made by Moderna targets two different coronavirus variants: the original virus from 2020 and the Omicron variant
An updated version of the COVID-19 vaccine made by Moderna that targets two coronavirus variants (known as a 바카라 사이트渂ivalent바카라 사이트� vaccine) has today been approved for adult booster doses by the Medicines and Healthcare products Regulatory Agency (MHRA) after it was found to meet the UK regulator바카라 사이트檚 standards of safety, quality and effectiveness.
The decision to grant approval for this booster vaccine in the UK was endorsed by the government바카라 사이트檚 independent expert scientific advisory body, the Commission on Human Medicines, after carefully reviewing the evidence.
In each dose of the booster vaccine, 바카라 사이트楽pikevax bivalent Original/Omicron바카라 사이트�, half of the vaccine (25 micrograms) targets the original virus strain from 2020 and the other half (25 micrograms) targets Omicron.
The MHRA바카라 사이트檚 decision is based on data from a clinical trial which showed that a聽 booster with the聽 bivalent聽 Moderna vaccine triggers a strong immune response against both Omicron (BA.1) and the original 2020 strain. In an exploratory analysis the bivalent vaccine was also found to generate a good immune response against the Omicron sub-variants BA.4 and BA.5.
Safety monitoring showed that the聽 side effects observed were the same as those seen for the original Moderna booster dose and were typically mild and self-resolving, and no serious safety concerns were identified.
Dr June Raine, MHRA Chief Executive said:
바카라 사이트淚 am pleased to announce the approval of the Moderna bivalent booster vaccine, which was found in the clinical trial to provide a strong immune response against the Omicron BA.1 variant as well as the original 2020 strain.
바카라 사이트淭he first generation of COVID-19 vaccines being used in the UK continue to provide important protection against the disease and save lives. What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve.
바카라 사이트淲e have in place a comprehensive safety surveillance strategy for monitoring the safety of all UK-approved COVID-19 vaccines and this will include the vaccine approved today.바카라 사이트�
Professor Sir Munir Pirmohamed, Chair of the Commission on Human Medicines said:
바카라 사이트淭he Commission on Human Medicines and its COVID-19 Vaccines Expert Working Group has independently reviewed the data on safety, quality and effectiveness and agrees with the MHRA바카라 사이트檚 decision.바카라 사이트�
바카라 사이트淭he virus, SARS-CoV-2, is continually evolving in order to evade the immunity provided by vaccines. This novel bivalent vaccine represents the next step in the development of vaccines to combat the virus, with its ability to lead to a broader immune response than the original vaccine.바카라 사이트�
The Joint Committee on Vaccination and Immunisation (JCVI)聽 will advise on聽 how this vaccine should be offered as part of the deployment programme.
Notes to editors
- The advises ministers on the safety, efficacy and quality of medicinal products. The CHM is an advisory non-departmental public body, sponsored by the바카라 사이트疍epartment of Health and Social Care.
- The MHRA바카라 사이트檚 Conditional Marketing Authorisation for the Moderna bivalent booster vaccine is valid in Great Britain only. An emergency use authorisation has been granted for Northern Ireland to ensure access across the whole of the United Kingdom. Both authorisations were made on the basis of the same rigorous evaluation of data.
- More information can be found in the聽product information
- A recent paper in a suggested that COVID-19 vaccines have prevented up to 20 million deaths in the first year of use